Dipeptidyl Peptidase-4 Inhibitors
Author:
Affiliation:
1. From the Department of Clinical Sciences, Division of Medicine, Lund University, Lund, Sweden
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://diabetesjournals.org/care/article-pdf/30/6/1344/597235/zdc00607001344.pdf
Reference52 articles.
1. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696–1705, 2006
2. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316–1322, 1992
3. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270–276, 1992
4. Nauck MA, Wollschlaeger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-[7–36amide]) in patients with NIDDM. Diabetologia 39:1546–1553, 1996
5. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830, 2002
Cited by 164 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Functional chia (Salvia hispanica L.) co-product protein hydrolysate: An analysis of biochemical, antidiabetic, antioxidant potential and physicochemical properties;Food Chemistry;2024-12
2. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management;Diabetologia;2024-08-19
3. Terpenoids as potential phytoconstituent in the treatment of diabetes: From preclinical to clinical advancement;Phytomedicine;2024-07
4. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides;Current Protein & Peptide Science;2024-05
5. Comparative analysis of newer classes of antidiabetics and the concept of pharmaceutical care – dealing with therapeutic problems;Pharmacia;2024-02-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3